We would like to inform you that, pursuant to Notice of Board meeting dated 6th February 2026 the Board Meeting of the Company was held today Friday 13th February 2026 at 3.00 p.m. at 4th ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Triochem Products' board approved its unaudited standalone financial results for Q3 FY26 and the nine months ended December 2025, which were reviewed by statutory auditors Kanu Doshi Associates LLP with an unqualified conclusion. Revenue from operations fell sharply to Rs 22.06 lakhs in Q3 FY26 from Rs 45.85 lakhs in Q3 FY25, a drop of about 52% year-on-year, though nine-month revenue was broadly flat at Rs 73.68 lakhs vs Rs 72.54 lakhs. The company slipped back into a loss, reporting a net loss after tax of Rs 13.18 lakhs for the quarter (vs a profit of Rs 8.83 lakhs last year) and Rs 35.50 lakhs for the nine months (vs a profit of Rs 5.17 lakhs). The board also noted the ongoing sale of immovable property, plant & machinery, and investment property in Maharashtra – a Material Related Party Transaction approved by shareholders via postal ballot on 13 December 2025, with assets reclassified as 'Held for Sale' under Ind AS 105 and sale expected by 31 March 2026.
Shareholders should note continued operating losses, a steep quarterly revenue decline, and that the company's turnaround now hinges on monetising non-core assets (book value ~Rs 57 lakhs vs fair value ~Rs 1,181 lakhs) to fund new ventures, which may support earnings once concluded but keeps near-term stock sentiment weak.